Evidence map›Paper›PMID 33297306›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Improving the Intercellular Uptake and Osteogenic Potency of Calcium Phosphate via Nanocomplexation with the RALA Peptide.

Michelle O'Doherty, Eoghan J Mulholland, Philip Chambers, Sreekanth Pentlavalli, Monika Ziminska, Marine J Chalanqui, Hannah M Pauly, Binulal N Sathy, Tammy H Donahue, Daniel J Kelly and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Michelle O'DohertySchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Eoghan J MulhollandSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-1200-9825
Philip ChambersSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Sreekanth PentlavalliSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-8513-1215
Monika ZiminskaSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-3600-1836
Marine J ChalanquiSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Hannah M PaulyDepartment of Biomedical Engineering, University Colorado State University, 1374 Campus Delivery, Fort Collins, CO 80523, USA.
Binulal N SathyTrinity Centre for Bioengineering, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Tammy H DonahueDepartment of Biomedical Engineering, University Colorado State University, 1374 Campus Delivery, Fort Collins, CO 80523, USA.
Daniel J KellyTrinity Centre for Bioengineering, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Nicholas DunneSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0003-4649-2410
Helen O McCarthySchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Queen's University Belfast · GBColorado State University · USRoyal College of Surgeons in Ireland · IETrinity College Dublin · IEUniversity of Massachusetts Amherst · US

Funding

Medical Research Council MC_PC_12021
6 · The paper itself

Abstract

Calcium phosphate-base materials (e.g., alpha tri-calcium phosphate (α-TCP)) have been shown to promote osteogenic differentiation of stem/progenitor cells, enhance osteoblast osteogenic activity and mediate in vivo bone tissue formation. However, variable particle size and hydrophilicity of the calcium phosphate result in an extremely low bioavailability. Therefore, an effective delivery system is required that can encapsulate the calcium phosphate, improve cellular entry and, consequently, elicit a potent osteogenic response in osteoblasts. In this study, collagenous matrix deposition and extracellular matrix mineralization of osteoblast lineage cells were assessed to investigate osteogenesis following intracellular delivery of α-TCP nanoparticles. The nanoparticles were formed via condensation with a novel, cationic 30 mer amphipathic peptide (RALA). Nanoparticles prepared at a mass ratio of 5:1 demonstrated an average particle size of 43 nm with a zeta potential of +26 mV. The average particle size and zeta potential remained stable for up to 28 days at room temperature and across a range of temperatures (4-37 °C). Cell viability decreased 24 h post-transfection following RALA/α-TCP nanoparticle treatment; however, recovery ensued by Day 7. Immunocytochemistry staining for Type I collagen up to Day 21 post-transfection with RALA/α-TCP nanoparticles (NPs) in MG-63 cells exhibited a significant enhancement in collagen expression and deposition compared to an untreated control. Furthermore, in porcine mesenchymal stem cells (pMSCs), there was enhanced mineralization compared to α-TCP alone. Taken together these data demonstrate that internalization of RALA/α-TCP NPs elicits a potent osteogenic response in both MG-63 and pMSCs.

Indexed as

bone engineeringcalcium phosphateintercellularosteogenicpeptideRALA

Identifiers

PMID33297306
PMCPMC7762210
OpenAlexW3111142704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.